EHR market will top $31 billion in 2018

As the healthcare industry continues to embrace emerging technology, the electronic health records market has continued to grow and will reach $31.5 billion in 2018, according to research from Kalorama Information, a division of MarketResearch.com. By 2022, the market is expected to rise to $39.7 billion, the firm predicted in its annual report.

The report looks at revenues for EMR/EHR systems, CPOE systems and directly related services, including installation, training, servicing and consulting. Cerner and Epic are the market leaders in the market, though there are still opportunities for new entrants in the space, according to the report. That is due to the lack of interoperability across systems. However, the cost of entering the market is the main drawback for smaller companies.

While the market will grow at a compound average rate of 6 percent from 2018 to 2022, there are varied participants, from hospitals and health systems, practice management systems, pharmacy services and others.

Among hospitals and health systems, Cerner, Epic, Allscripts and athenahealth are the market leaders, which assist hospitals with their clinical processes via EMR. The same companies, plus MEDITECH, are the top companies for smaller hospitals with one to 200 beds. Cerner, Allscripts and Epic also lead the way for practice management system acquirers.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.